JP2020505049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505049A5 JP2020505049A5 JP2019541188A JP2019541188A JP2020505049A5 JP 2020505049 A5 JP2020505049 A5 JP 2020505049A5 JP 2019541188 A JP2019541188 A JP 2019541188A JP 2019541188 A JP2019541188 A JP 2019541188A JP 2020505049 A5 JP2020505049 A5 JP 2020505049A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- recombinant adenovirus
- cancer
- site
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 33
- 125000003729 nucleotide group Chemical group 0.000 claims 33
- 241000701161 unidentified adenovirus Species 0.000 claims 27
- 230000001225 therapeutic effect Effects 0.000 claims 21
- 108700019146 Transgenes Proteins 0.000 claims 20
- 238000003780 insertion Methods 0.000 claims 17
- 230000037431 insertion Effects 0.000 claims 17
- 238000012217 deletion Methods 0.000 claims 14
- 230000037430 deletion Effects 0.000 claims 14
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims 5
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000835 fiber Substances 0.000 claims 3
- 108010079709 Angiostatins Proteins 0.000 claims 2
- 101710113110 B-cell receptor-associated protein 31 Proteins 0.000 claims 2
- 108010079505 Endostatins Proteins 0.000 claims 2
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 claims 2
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 2
- 101710139711 IkB-like protein Proteins 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 2
- 101710081123 Interleukin-27 subunit alpha Proteins 0.000 claims 2
- 101710116301 Interleukin-27 subunit beta Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 102000012936 Angiostatins Human genes 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- -1 CD86 Proteins 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims 1
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 1
- 101001049954 Human adenovirus C serotype 2 Early 4 ORF6 protein Proteins 0.000 claims 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102100039897 Interleukin-5 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102000000585 Interleukin-9 Human genes 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 102000003898 interleukin-24 Human genes 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452342P | 2017-01-30 | 2017-01-30 | |
| US62/452,342 | 2017-01-30 | ||
| US201762520945P | 2017-06-16 | 2017-06-16 | |
| US62/520,945 | 2017-06-16 | ||
| PCT/US2018/016032 WO2018140973A1 (en) | 2017-01-30 | 2018-01-30 | Multiple transgene recombinant adenovirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505049A JP2020505049A (ja) | 2020-02-20 |
| JP2020505049A5 true JP2020505049A5 (enExample) | 2021-03-11 |
Family
ID=62978741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541188A Pending JP2020505049A (ja) | 2017-01-30 | 2018-01-30 | 複数トランスジーン組み換えアデノウイルス |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190352616A1 (enExample) |
| EP (1) | EP3574090A4 (enExample) |
| JP (1) | JP2020505049A (enExample) |
| KR (1) | KR20190128634A (enExample) |
| CN (1) | CN110741080A (enExample) |
| AU (1) | AU2018213417A1 (enExample) |
| BR (1) | BR112019015600A2 (enExample) |
| CA (1) | CA3052090A1 (enExample) |
| IL (1) | IL268291A (enExample) |
| MX (1) | MX2019008921A (enExample) |
| SG (1) | SG11201906973TA (enExample) |
| WO (1) | WO2018140973A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| CA3064892A1 (en) * | 2017-05-24 | 2018-11-29 | Epicentrx, Inc. | Anti-angiogenic adenovirus |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2022007800A1 (zh) * | 2020-07-06 | 2022-01-13 | 嘉兴安宇生物科技有限公司 | 一种非洲猪瘟的重组腺病毒疫苗及其构建方法 |
| EP4349975A4 (en) * | 2021-05-25 | 2025-04-16 | Voncolytic Therapeutics Co., Ltd. | Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment |
| CN113249342B (zh) * | 2021-05-25 | 2023-12-01 | 江苏万戎生物医药科技有限公司 | 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100896483B1 (ko) * | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
| HUE046565T2 (hu) * | 2009-03-02 | 2020-03-30 | Univ California | Tumorszelektív adenovírus E1A és E1B mutánsok |
| US20130195800A1 (en) * | 2010-03-23 | 2013-08-01 | Intrexon Corporation | Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof |
| BR112013006699A2 (pt) * | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
| US11155599B2 (en) * | 2012-02-02 | 2021-10-26 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
| DK3461491T3 (da) * | 2013-04-18 | 2025-02-03 | Tilt Biotherapeutics Oy | Forbedret adoptiv celleterapi |
| CN103614416B (zh) * | 2013-09-30 | 2016-09-07 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 |
| PL3198009T3 (pl) * | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-01-30 US US16/482,055 patent/US20190352616A1/en not_active Abandoned
- 2018-01-30 AU AU2018213417A patent/AU2018213417A1/en not_active Abandoned
- 2018-01-30 CA CA3052090A patent/CA3052090A1/en active Pending
- 2018-01-30 CN CN201880021787.6A patent/CN110741080A/zh active Pending
- 2018-01-30 EP EP18743942.7A patent/EP3574090A4/en not_active Withdrawn
- 2018-01-30 BR BR112019015600-3A patent/BR112019015600A2/pt not_active Application Discontinuation
- 2018-01-30 SG SG11201906973TA patent/SG11201906973TA/en unknown
- 2018-01-30 MX MX2019008921A patent/MX2019008921A/es unknown
- 2018-01-30 WO PCT/US2018/016032 patent/WO2018140973A1/en not_active Ceased
- 2018-01-30 KR KR1020197025498A patent/KR20190128634A/ko not_active Ceased
- 2018-01-30 JP JP2019541188A patent/JP2020505049A/ja active Pending
-
2019
- 2019-07-28 IL IL268291A patent/IL268291A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516293A5 (enExample) | ||
| Ding et al. | Epithelial‐to‐mesenchymal transition of murine liver tumor cells promotes invasion | |
| JP2020521470A5 (enExample) | ||
| Xiao et al. | Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer | |
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| RU2016120618A (ru) | Онколитический hsv-вектор | |
| Yoon et al. | CRISPR-Cas12a with an oAd induces precise and cancer-specific genomic reprogramming of EGFR and efficient tumor regression | |
| Hung et al. | Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice | |
| US7482156B2 (en) | Hepatocellular carcinoma specific promoter and uses thereof | |
| JP2020516293A (ja) | 複数トランスジーン組み換えアデノウイルス | |
| WO2014036807A1 (zh) | 重组单纯疱疹病毒、其制备方法及应用 | |
| Chen et al. | Contribution of tumor heterogeneity in a new animal model of CNS tumors | |
| Ito et al. | Genomic and transcriptional alterations of cholangiocarcinoma | |
| Matrka et al. | Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence | |
| CN102796709A (zh) | 肝癌特异性基因-病毒及其应用 | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| RU2011136280A (ru) | HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ | |
| Riederer et al. | Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease | |
| WO2020230785A1 (ja) | 細胞融合を誘導するワクシニアウイルス及びその利用 | |
| CN106318915A (zh) | 重组单纯疱疹病毒HSV‑hTERTp_ICP4_LungCA‑GFP及诊断试剂盒 | |
| WO2020011754A1 (en) | Chimeric vaccinia viruses | |
| CN101671666B (zh) | 用于恶性肿瘤基因治疗的增殖和肿瘤细胞特异性基因操纵系统 | |
| An et al. | Road of no return—loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer | |
| CN103484462A (zh) | Survivin启动子调控CD基因的重组腺病毒载体构建及其应用 | |
| RU2018115534A (ru) | Противоопухолевая композиция |